Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
International Journal of Pharmaceutics|September 3, 2013
The effect of lipid composition and liposome size on the release properties of liposomes-in-hydrogelJulia Hurler, Simon Žakelj, Janez Mravljak, et al.
Pharmaceutics|November 19, 2020
Echinacea angustifolia DC. Lipophilic Extract Patch for Skin Application: Preparation, In Vitro and In Vivo StudiesDritan Hasa, Simon Žakelj, Iztok Grabnar, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|May 3, 2025
A novel butyrylcholinesterase inhibitor induces antidepressant, pro-cognitive, and anti-anhedonic effects in Flinders Sensitive Line rats: The role of the ghrelin-dopamine cascadeNadia Olivier, Brian H Harvey, Stanislav Gobec, et al.
Antibiotics (Basel, Switzerland)|August 6, 2021
A Fine-Tuned Lipophilicity/Hydrophilicity Ratio Governs Antibacterial Potency and Selectivity of Bifurcated Halogen Bond-Forming NBTIsAnja Kolarič, Maja Kokot, Martina Hrast, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 7, 2013
Monitoring of imatinib targeted delivery in human leukocytesEva Kralj, Simon Žakelj, Jurij Trontelj, et al.
Chemico-Biological Interactions|August 1, 2025
N-Propargylpyrrolidine-based butyrylcholinesterase and monoamine oxidase inhibitorsUrban Košak, Damijan Knez, Anja Pišlar, et al.
European Journal of Medicinal Chemistry|May 8, 2020
N-alkylpiperidine carbamates as potential anti-Alzheimer's agentsUrban Košak, Nika Strašek, Damijan Knez, et al.
Scientific Reports|September 14, 2021
Treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitorMaja Zakošek Pipan, Sonja Prpar Mihevc, Malan Štrbenc, et al.
Scientific Reports|September 15, 2017
Identification and characterization of the novel reversible and selective cathepsin X inhibitorsUrša Pečar Fonović, Ana Mitrović, Damijan Knez, et al.
European Journal of Medicinal Chemistry|July 23, 2018
Multi-target-directed ligands for treating Alzheimer's disease: Butyrylcholinesterase inhibitors displaying antioxidant and neuroprotective activitiesDamijan Knez, Nicolas Coquelle, Anja Pišlar, et al.
Pageof 3